Safety, Three Batches Consistency and Immunity Duration of the Post-marketing Inactivated Enterovirus Type 71 (EV71) Vaccine in Children Aged 6-71 Months

Beijing Chaoyang District Centre for Disease Control and Prevention

Status and phase: Unknown; Phase 4

Conditions: Hand Foot and Mouth Disease

Treatments: Biological: the first batch vaccine; Biological: the third batch vaccine; Biological: the second batch vaccine

Study type: Interventional

Funder types: Other

Identifiers

NCT02889497

cycdc2016-6

Details and patient eligibility

About

This study evaluates the safety,three batches consistency and immunity duration of the post-marketing inactivated Enterovirus Type 71 (EV71) vaccine in children aged 6-71 months.This study has two groups:safety observation group and immunogenicity observation group.20000 subjects will receive 2 doses vaccines and be observed for safety among 2 epidemic cycles of HFMD.In the immunogenicity observation group, 900 subjects will be randomly received 3 batches vaccines(2 doses),and blood sampled at days 0 and 56.

Enrollment: 20,900 estimated patients

Sex: All

Ages: 6 to 71 months old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• 8 Months to 71 Months (Healthy Children or Infants)；
• Providing the subjects' legal identity certificate (birth certificate , residence booklet or ID card) and vaccination certificate, legal guardians can provide legal identity proof (resident booklet or ID card) so that the doctor can determine the subject identity to complete recruitment program；
• The subjects' guardians are able to understand and sign the informed consent voluntary. Guardians have the ability to use the thermometer ,dividing ruler and can fill out the Diary card ,follow-up card according to requirements；
• Persist for a 24 months visit.If doubtful HFMD case happen，the subject's guardian should send the subject to the medical institutions at above the county level and report this case to the investigator.The subjects who participate immunogenicity observation group can receive sample collection including blood，throat swab or anal awab according to program requirements.

Exclusion criteria

• Exclusion Criteria for the first dose:

  • Subject with clinical diagnosis or suspect HFMD（Especially the history of herpangina）；
  • Subject that has a medical history of any of the following: allergic history, or allergic to any ingredient of vaccine；
  • History of seizures,convulsions or twitching ;Family history of progressive neurological disease；
  • Autoimmune disease or immunologic deficiency.Any prior administration of immunodepressant in last 6month；
  • History of asthma，thyroid ablation，angioneurotic edema, diabetes mellitus or malignant tumour；
  • Alienia，functional asplenia，or any condition that cause asplenia or splenectomy；
  • Diagnosed coagulation abnormalities (such as clotting factor deficiency, coagulation disorders, platelet disorder) or significant bruising or blood clotting disorder；
  • Any acute disease or chronic disease attack in last 7 days；
  • Any prior administration of blood products in last 3 month；
  • Any prior administration of attenuated live vaccine in last 15 days , subunit or inactivated vaccines in last 7 days；
  • Fever before vaccination, axillary temperature ﹥37.0℃；
  • Attend Other vaccine or drug clinical trials concurrent in 6 months；
  • Any condition that in the opinion of the investigator。

• Exclusion Criteria for the second dose:

  • Any exclusion criteria for the first dose happens after been enrolled；
  • Newly HFMD diagnosed patients after been enrolled；
  • Any condition that in the opinion of the investigator or ethics committee think should be eliminated.

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

20,900 participants in 3 patient groups

300 subjects receive the first batch vaccine

Experimental group

Description:

300 subjects will be randomly received the first batch vaccine

Treatment:

Biological: the first batch vaccine

300 subjects receive the second batch vaccine

Experimental group

Description:

300 subjects will be randomly received the second batch vaccine

Treatment:

Biological: the second batch vaccine

300 subjects receive the third batch vaccine

Experimental group

Description:

300 subjects will be randomly received the third batch vaccine

Treatment:

Biological: the third batch vaccine